-

Bicara Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, today announced that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA, on Wednesday, January 11, 2023 at 9:30 am PST.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study. Bicara’s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy. More information is available at www.bicara.com.

Contacts

Investors
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
212-362-1200

Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936

Bicara Therapeutics


Release Versions

Contacts

Investors
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
212-362-1200

Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936

More News From Bicara Therapeutics

Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present dose expansion data from the ongoing Phase 1/1b clinical trial of its lead investigational candidate, BCA101, in combination with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. BCA101 is a first in class dual-action bifunctional antibody des...

Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the publication of a manuscript in Cancer Research, a journal of the American Association for Cancer Research (AACR), describing the design and characterization of its lead program, BCA101, a first in class dual-action bifunctional antibody designed to inhibit EGFR and disable TGF-β directly at the tumor s...

Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics to present preclinical data supporting the ongoing clinical development of the lead investigational candidate BCA101 at AACR 2023....
Back to Newsroom